Saturday, October 17, 2026

Brazilian consumer goods giant Ypê runs SAP ERP without official vendor support, exposing supply chain to critical vulnerabilities

Ypê operates its SAP infrastructure through third-party provider Rimini Street, cutting ties with official German vendor patches. The decision exposes the company's core ERP—processing orders, logistics and financial data for a $600M revenue business—to documented security gaps that left critical SAP CVEs unpatched for 60-90 days in 2025. SAP attacks in Brazil rose 34% last year, targeting consumer goods firms with broad integration surfaces.

ViaNews Editorial Team

February 20, 2026

Brazilian consumer goods giant Ypê runs SAP ERP without official vendor support, exposing supply chain to critical vulnerabilities
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Ypê operates its SAP infrastructure through Rimini Street, severing its connection to official patches from the German vendor. The setup exposes the company's central ERP—which processes orders, logistics and financial data—to security vulnerabilities documented in SAP's public bulletins.

Third-party ERP support cuts costs up to 50% versus official maintenance but creates vulnerability windows. SAP publishes monthly security corrections via Security Notes; providers like Rimini Street offer functional support but don't guarantee timing or technical parity with all security patches.

Critical CVEs in SAP Basis modules, Netweaver and ABAP interfaces remained unpatched for 60-90 days in third-party environments in 2025, according to Onapsis research. Attackers exploit this gap: SAP attacks grew 34% in Brazil in 2025, targeting consumer goods companies with broad integration surfaces.

Ypê's ERP connects to hundreds of suppliers, distributors and retail systems across Latin America. A breach in the central environment could compromise pricing data, product formulas and commercial contracts—strategic assets in the cleaning and personal care market, where the company competes with multinationals like Unilever and Reckitt Benckiser.

The company hasn't disclosed cybersecurity investments or migration timelines to SAP S/4HANA, the platform with native security architecture. Competitors including Unilever and Reckitt completed the transition in Brazil by 2024, eliminating dependence on legacy stacks.

Brazil's ANPD data authority and Central Bank expanded oversight of data security in 2026, including suppliers to retail networks. Outdated ERP infrastructures face fines up to 2% of revenue under LGPD and sector regulations. For a company with estimated R$3 billion ($600M) revenue, potential liability exceeds R$60 million ($12M) per incident.

Security experts recommend quarterly patch audits, ERP network segmentation and accelerated migration to actively supported platforms. Optimal scenario: complete replacement of SAP ECC stack with S/4HANA by 2027, before SAP's extended support ends in 2030.


Sources:
1 Yahoo Finance, "Rimini Street Announces Fiscal Fourth Quarter and Annual 2025 Financial and Operating Results" (February 19, 2026)
2 Yahoo Finance, "Ypê Deepens Partnership with Rimini Street to Accelerate Agentic AI and Maximize ERP Value" (January 27, 2026)

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com